RESEARCHER PROFILE

Rodrigo Dienstmann

← Back to Universitat de Vic - Universitat Central de Catalunya

R

Universitat de Vic - Universitat Central de Catalunya

Cancer Genomics and DiagnosticsColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsGenetic factors in colorectal cancer

Rodrigo Dienstmann works in Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Genetic factors in colorectal cancer. Recorded institutional associations include Universitat de Vic - Universitat Central de Catalunya, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari.

689Publications
21,018Citations
60H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. The consensus molecular subtypes of colorectal cancer

    2015 · 5,142 citations
  2. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

    2020 · 1,186 citations
  3. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

    2017 · 1,021 citations
  4. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

    2018 · 815 citations
  5. Development of PI3K inhibitors: lessons learned from early clinical trials

    2013 · 766 citations
  6. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer

    2017 · 624 citations
  7. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

    2018 · 519 citations
  8. Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

    2014 · 462 citations
  9. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

    2024 · 415 citations
  10. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

    2015 · 388 citations
  11. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

    2013 · 365 citations
  12. A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations

    2018 · 359 citations
  13. Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs

    2010 · 355 citations
  14. Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients

    2015 · 343 citations
  15. Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes

    2014 · 330 citations
  16. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    2018 · 268 citations
  17. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies

    2017 · 255 citations
  18. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study

    2017 · 237 citations
  19. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

    2023 · 234 citations
  20. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer

    2019 · 228 citations
  21. Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis

    2020 · 191 citations
  22. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

    2017 · 187 citations
  23. Erratum: Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

    2017 · 183 citations
  24. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

    2015 · 178 citations
  25. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

    2014 · 173 citations

← Return to the university profile